A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Ascendis Pharma A/S
Eikon Therapeutics
ModernaTX, Inc.
Verastem, Inc.
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Ascendis Pharma A/S
Essen Biotech
Synthorx, Inc, a Sanofi company
VM Oncology, LLC
Transgene
BioInvent International AB
Eisai Inc.
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Mirati Therapeutics Inc.
Immuneering Corporation
Qurient Co., Ltd.
NuCana plc
Medicenna Therapeutics, Inc.
BioAtla, Inc.
Sanofi
Merck Sharp & Dohme LLC
Providence Health & Services
Fred Hutchinson Cancer Center
Phanes Therapeutics
Vaccinex Inc.
CJ Bioscience, Inc.
Nykode Therapeutics ASA
NextCure, Inc.
Immodulon Therapeutics Ltd
GI Innovation, Inc.
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
University of California, Davis
Augusta University
SQZ Biotechnologies
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
M.D. Anderson Cancer Center
Incyte Corporation
MultiVir, Inc.
ETOP IBCSG Partners Foundation